News & Updates
Filter by Specialty:
Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term
A post-hoc analysis of a phase III trial of long-term safinamide for Parkinson’s disease (PD) finds a significant early increase in pre-existing dyskinesia as well as improved motor symptoms in patients with or without pre-existing dyskinesia at 1 year.
Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term
12 Oct 2022
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
11 Oct 2022
Telmisartan does not deliver in peripheral arterial disease
Treatment with the angiotensin receptor blocker telmisartan does not appear to confer improvements on walking performance in patients with lower extremity peripheral artery disease (PAD), according to the TELEX trial.
Telmisartan does not deliver in peripheral arterial disease
11 Oct 2022
Osimertinib plus selumetinib shows promise in advanced NSCLC
The combination of osimertinib plus selumetinib exhibits antitumour activity in patients with MET-negative, EGFRm advanced nonsmall cell lung cancer (NSCLC), with the safety profile consistent with the reported safety data for the drugs, according to data from the small open-label, phase Ib study.
Osimertinib plus selumetinib shows promise in advanced NSCLC
11 Oct 2022
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
Patients with complicated urinary tract infection (UTI) or acute pyelonephritis caused by gram-negative pathogens may fare better with cefepime/enmetazobactam than with piperacillin/tazobactam, as the former is associated with a greater likelihood of achieving treatment success, according to the results of a phase III trial.
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
11 Oct 2022
Liver stiffness, but not fatty liver disease, linked to atrial fibrillation
Fatty liver disease does not seem to contribute to prevalent or incident atrial fibrillation (AF), but higher liver stiffness does, particularly among individuals without steatosis, reports a recent study.
Liver stiffness, but not fatty liver disease, linked to atrial fibrillation
11 Oct 2022
HBV elimination goals set by WHO not attainable, experts say
Current efforts to eradicate hepatitis B virus (HBV), including vaccination, screening, and treatment strategies, do not seem enough to achieve the elimination goals set by the World Health Organization (WHO), suggests a recent study.